Q32 Bio
Developing therapies targeting powerful regulators of innate and adaptive immunity to rebalance the immune system in severe autoimmune and inflammatory diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD409m (Public information from Nov 2023)
Cambridge Massachusetts (HQ)
Authorizing premium user...